Hepatitis C
CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]
- Details
- Category: HCV Treatment
- Published on Sunday, 24 March 2013 00:00
The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.
[Produced in collaboration with IFARA]
In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.
CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection
- Details
- Category: HCV Treatment
- Published on Wednesday, 20 March 2013 00:00
New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.
CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the Phase 2a COSMOS trial, according to a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 06 March 2013 00:00
Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.
Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.
CROI 2013: Progress in Hepatitis C Drug Development [VIDEO]
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 04 March 2013 00:00
Hepatitis C and its treatment has been a key focus at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013), taking place this week in Atlanta. Investigators gave an overview of their research and projections about forthcoming approvals of direct-acting antiviral agents at a morning press conference on Monday.
More Articles...
- CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response
- Milk Thistle Drug May Help Control HCV Replication after Liver Transplant
- NS5A Inhibitor Daclatasvir Has Dual Mode of Action Against Hepatitis C Virus
- Liver Cancer Increasing among People with HIV/HCV Coinfection
- Updated Boceprevir (Victrelis) Label Adds Data on Prior Null Responders
Web Design and Development by